Cancer Research Annual Meeting 2010 Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaidi, A.
Right arrow Articles by Paraskeva, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaidi, A.
Right arrow Articles by Paraskeva, C.
[Cancer Research 66, 6683-6691, July 1, 2006]
© 2006 American Association for Cancer Research

Cell, Tumor, and Stem Cell Biology

Direct Transcriptional Up-regulation of Cyclooxygenase-2 by Hypoxia-Inducible Factor (HIF)-1 Promotes Colorectal Tumor Cell Survival and Enhances HIF-1 Transcriptional Activity during Hypoxia

Abderrahmane Kaidi, David Qualtrough, Ann C. Williams and Christos Paraskeva

Cancer Research UK Colorectal Tumour Biology Research Group, Department of Cellular and Molecular Medicine, Faculty of Medical and Veterinary Science, University Bristol, Bristol, United Kingdom

Requests for reprints: Christos Paraskeva, Cancer Research UK Colorectal Tumour Biology Research Group, Department of Cellular and Molecular Medicine, Faculty of Medical and Veterinary Science, Bristol University, BS8 1TD, Bristol, United Kingdom. Phone: 117-928-7894; Fax: 117-928-7896; E-mail: c.paraskeva{at}bristol.ac.uk.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Cyclooxygenase (COX)-2, the inducible key enzyme for prostanoid biosynthesis, is overexpressed in most colorectal carcinomas and a subset of colorectal adenomas. Genetic, biochemical, and clinical evidence indicates an important role for COX-2 in colorectal tumorigenesis. Although COX-2 can be induced by aberrant growth factor signaling and oncogene activation during colorectal tumorigenesis, the role of microenvironmental factors such as hypoxia in COX-2 regulation remains to be elucidated. For the first time, we report that under hypoxic conditions COX-2 protein levels increase in colorectal adenoma and carcinoma cells. Rigorous analyses reveal that COX-2 up-regulation is transcriptional and is associated with hypoxia-inducible factor (HIF)-1{alpha} induction. Oligonucleotide pull-down and chromatin immunoprecipitation assays reveal that HIF-1{alpha} binds a hypoxia-responsive element on the COX-2 promoter. COX-2 up-regulation during hypoxia is accompanied by increased levels of prostaglandin E2 (PGE2), which promote tumor cell survival under hypoxic conditions. In addition, elevated levels of PGE2 in hypoxic colorectal tumor cells enhance vascular endothelial growth factor expression and HIF-1 transcriptional activity by activating the mitogen-activated protein kinase pathway, showing a potential positive feedback loop that contributes to COX-2 up-regulation during hypoxia. This study identifies COX-2 as a direct target for HIF-1 in colorectal tumor cells. In addition, COX-2 up-regulation represents a pivotal cellular adaptive response to hypoxia with implication for colorectal tumor cell survival and angiogenesis. We propose that using modified COX-2-selective inhibitors, which are only activated under hypoxic conditions, could potentially be a novel more selective strategy for colorectal cancer prevention and treatment. (Cancer Res 2006; 66(13): 6683-91)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Colorectal cancer results from the accumulation of intrinsic genetic and epigenetic changes that alter signaling pathways, which regulate cell proliferation, differentiation, and cell death (1) as well as the selection process imposed by environmental and microenvironmental factors, which ultimately leads to clonal evolution and tumor progression (2). Cyclooxygenase (COX)-2 is overexpressed in most colorectal carcinomas and a subset of adenomas (3, 4), and accumulating evidence supports an important role for COX-2 in colorectal tumorigenesis (5). COX-2-selective inhibitors have a potent antitumor effect in vitro (6, 7) and in vivo (8), and genetic depletion of the COX-2 gene results in a marked decrease in adenoma burden in the Apc{Delta}716 mouse model of intestinal tumorigenesis (9). Enhanced COX-2 expression in colon cancer cells results in increased levels of proangiogenic factors, such as vascular endothelial growth factor (VEGF), thus the promotion of angiogenesis (10). COX-2, like its isoenzyme COX-1, catalyses the conversion of arachidonic acid to endoperoxide intermediates, which are ultimately converted to prostanoids. Recent evidence points to an important role for the COX-2 downstream metabolite prostaglandin E2 (PGE2) in colorectal tumorigenesis (11). Increased levels of PGE2 were reported in human colorectal cancers and adenomas in familial adenomatous polyposis (FAP) patients (12). Additionally, PGE2 can stimulate cell proliferation and motility (13) while inhibiting apoptosis in colorectal cancer cells (14). More recently, PGE2 was shown to enhance intestinal adenoma growth via activation of the Ras–mitogen-activated protein kinase (MAPK) cascade in Apcmin mice (15). Given the critical role for COX-2 up-regulation in colorectal cancer and other cancers, it is important to achieve a greater understanding of the regulatory networks that control COX-2 expression.

Numerous factors, including growth factors, cytokines, oncogenes, and tumor promoters, stimulate COX-2 transcription via transcription factors, such as activator protein, NF-IL6, NF-{kappa}B, NFAT, and PEA3 (5). In the context of colorectal tumorigenesis, although mutations resulting in aberrant Wnt and Ras signaling have been implicated in COX-2 up-regulation (16), the role of microenvironmental factors, such as hypoxia in COX-2 regulation during colorectal tumorigenesis, has not been investigated.

Hypoxia, which refers to oxygen deficiency in tissues, is a universal hallmark of solid tumors and it represents a key regulatory factor in tumor growth and survival (17). Although, the hypoxic microenvironment is thought to be associated with tumor progression (18), persistent hypoxia can also result in cell death (19). Therefore, hypoxia represents an important selection pressure that drives clonal progression of tumors (20). Adaptation to hypoxia is critical for tumor cell survival and is mediated largely by activation of genes that facilitate short-term adaptation (e.g., increased vascular permeability) as well as long-term adaptive mechanisms (e.g., angiogenesis; refs. 17, 21, 22).

The coordinated homeostatic response to hypoxia is largely transcriptional and is mediated primarily through the activation of the heterodimeric transcription factor hypoxia-inducible factor (HIF)-1 (23). HIF-1 is composed of two subunits: the oxygen-sensitive HIF-1{alpha} and the constitutively expressed HIF-1ß subunit (23). In normoxia, HIF-1{alpha} is hydroxylated at key proline residues facilitating von Hippel-Lindau protein binding, which in turn allows ubiquitination and subsequent proteasome-targeted degradation (24). Under hypoxic conditions, proline hydroxylation is inhibited, thereby stabilizing HIF-1{alpha}, which can then translocate into the nucleus and bind to constitutively expressed HIF-1ß, forming the active HIF-1 complex (25). The HIF-1 complex recruits the transactivator p300/CBP, resulting in enhanced transcriptional activity (26). HIF-1 binds a conserved DNA consensus on promoters of its target genes known as the hypoxia-responsive element (HRE; ref. 23). The core sequence of the HRE is 5'-CGTG-3', and the optimum mammalian HRE was defined to be 5'-B(A/G)CGTGVBBB-3' (where B refers to all bases except A and V refers to all bases except T; ref. 27).

HIF-1{alpha} is overexpressed in various types of cancer, including colorectal cancer (28), and compelling evidence supports a role for HIF-1 in tumorigenesis (29, 30). The HIF-1 transcriptional response largely allows cellular adaptation to the hypoxic microenvironment (31). Therefore, identification and characterization of the mechanisms underlying the adaptive responses to hypoxia are vital for an increased understanding of the tumorigenic process and, most importantly, for the development of novel therapeutic approaches.

Because COX-2 expression increases during colorectal tumor progression (3, 4) and given the key role of COX-2 in colorectal tumorigenesis (9), we hypothesized that COX-2 may be a hypoxia-responsive gene whose up-regulation may facilitate adaptation to cellular stress imposed by hypoxia. Indeed, we describe a novel mechanism for COX-2 up-regulation in colorectal tumor cells during hypoxia through HIF-1. During hypoxia, COX-2 up-regulation results in higher levels of PGE2, which then promotes colorectal tumor cell survival. We also report that PGE2 can enhance HIF-1 transcriptional activity and VEGF induction under hypoxic conditions. Collectively, our results identify COX-2 up-regulation as a critical adaptive response to hypoxia with implications for colorectal tumor cell survival and angiogenesis.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell culture and treatments. The carcinoma cell lines HT29 and HCT116 were from the American Type Culture Collection (ATCC; Rockville, MD) and cultured in DMEM or McCoy's 5A media supplemented with 10% fetal bovine serum, respectively. The adenoma cell line AA/C1 was derived in this laboratory and maintained as described previously (2). AA/C1 is derived from a single adenoma from a patient with FAP, and AA/C1/SB10C represents an in vitro–transformed variant of AA/C1 (2). For hypoxic exposure, cells were placed in a modulator-incubator in an atmosphere consisting of 94% N2, 5% CO2, and 1% O2. PGE2, the COX-2-selective inhibitor NS-398, and the hypoxia surrogate deferoxamine were from Sigma (Poole, United Kingdom). The MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor U0126 was from Cell Signalling Technology (Danvers, MA). The HIF-1{alpha} inhibitor YC-1 (32), also an activator of soluble guanylyl cyclase, was from Cayman Europe (Tallinn, Estonia).

Determination of cell yield and cell death. After treatment, the cell yield was determined by counting the adherent cells. The level of cell death was assessed by measuring the proportion of floating apoptotic cells, which had detached from the tissue culture flask, and cell death was represented as a percentage of total cell number as described previously (33). The induction of cell death was characterized as apoptotic both morphologically (following acridine orange staining) and biochemically as shown by poly(ADP-ribose) polymerase cleavage as described in detail previously (33).

Cell cycle analysis. Adherent HT29 cells were collected and fixed in 70% ethanol. Cells were resuspended in PBS containing 10 µg/mL propidium iodide (Sigma) and 5 µg/mL RNaseA (Sigma) and incubated at room temperature for 30 minutes before fluorescence-activated cell sorting analysis was done using a FACScan (BD Biosciences, Oxford, United Kingdom). Data analysis was done using Cell Quest software (BD Biosciences).

Transient transfection and reporter assays. The expression vector pcDNA3/HIF-1{alpha}/P402A+P564G (generous gift from Peter Ratcliffe, University of Oxford, Oxford, United Kingdom) encodes a mutant version of HIF-1{alpha}, which is resistant to degradation (34). HT29 cells were transiently transfected with either HIF-1{alpha} expression plasmid or empty vector (pcDNA3) plasmid using Tfx (Promega, Southampton, United Kingdom) following the manufacturer's protocol.

The HRE reporter p11w was from the ATCC, and the COX-2 promoter reporter was a generous gift from Stephen Prescott (University of Utah, Salt Lake City, UT). COX-2 promoter deletions were carried out starting from the full-length COX-2 promoter using unique restriction sites and subcloned into a pGL3-basic vector. For luciferase reporter assays, HT29 cells were transfected with the firefly luciferase reporter construct and the control renilla luciferase reporter pRL-SV40 using Tfx reagent. After treatment, the luciferase activity was measured using the dual-luciferase reporter assay system (Promega) following the manufacturer's protocol.

Western blot analysis. Whole-cell extracts were prepared by lysing cells with Cell Signalling Technology lysis buffer supplemented with protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Protein concentration was quantified using Bio-Rad DC protein assay kit (Bio-Rad, Hemel Hempstead, United Kingdom). Protein lysates were resolved on SDS-PAGE, and proteins were detected by Western blotting with mouse monoclonal antibodies against HIF-1{alpha}, HIF-1ß (BD Biosciences), COX-2 (Cayman Europe), and {alpha}-tubulin (Sigma) and rabbit antibodies against ERK and pERK using enhanced chemiluminescence detection system (Kirkegaard & Perry Laboratories, Gaithersburg, MD).

RNA extraction and Northern analysis. Total RNA was isolated using the RNeasy kit (Qiagen, Crawley, United Kingdom). RNA (20 µg) samples were resolved on a 1% formaldehyde agarose gel and analyzed by Northern blotting. COX-2 mRNAs were detected using a biotinylated human COX-2 probe. The COX-2 probe was prepared by amplifying a fragment from COX-2 cDNA using the biotinylated primers: forward primer (5'-GTGCCTGATGATTGCCCGACTCC-3') and reverse primer (5'-TGTTGTGTTCCCGCAGCCAGATTG-3'). Visualization was carried out using the nonradioactive North2South hybridization and detection kit (Pierce Biotechnology, Rockford) following the manufacturer's protocol.

Extraction of nuclear DNA-binding proteins. Extraction of DNA-binding proteins from HT29 cells was done following a standard procedure. Briefly, HT29 cells were washed with ice-cold PBS and resuspended in 400 µL ice-cold low-salt buffer [10 mmol/L HEPES-KOH (pH 7.9), 1.5 mmol/L MgCl2, 10 mmol/L KCl, 0.5 mmol/L DTT, 0.2 mmol/L aminoethyl-benzenesulfonyl fluoride]. The nuclei were collected by centrifugation and then resuspended in 40 µL ice-cold high-salt buffer [20 mmol/L HEPES-KOH (pH 7.9), 25% v/v glycerol, 420 mmol/L NaCl, 1.5 mmol/L MgCl2, 0.2 mmol/L EDTA, 0.5 mmol/L DTT, 1 mmol/L phenylmethylsulfonyl fluoride] and incubated on ice for 20 minutes, and then the lysates were cleared by centrifugation.

Oligonucleotide pull-down assay. Nuclear DNA-binding protein extracts (100 µg) were incubated at 30°C for 10 minutes with either 0.5 nmol 5'-biotinylated double-stranded wild-type (WT) oligonucleotide (5'-ATTTTCTCATTTCCGTGGGTAAAAAACCCT-3') or mutant oligonucleotide (5'-ATTTTCTCATTTCTACAGGTAAAAAACCCT-3') (Sigma-Genosys, Haverhill, United Kingdom) coupled previously to streptavidin agarose beads (Sigma). After incubation, the biotinylated oligonucleotide-coupled streptavidin beads were washed six times. Samples were denatured in SDS sample buffer and subjected to SDS-PAGE. HIF-1{alpha} was detected by Western blotting. For the competition assay, excess nonbiotinylated oligonucleotides were used.

Chromatin immunoprecipitation assay. The procedure was done using chromatin immunoprecipitation (ChIP) kit (Upstate, Lake Placid, NY). Briefly, HT29 cells growing in T25 flasks under normoxia or hypoxia were cross-linked using 1% formaldehyde at 37°C for 10 minutes. After washing with PBS, cells were resuspended in 300 µL lysis buffer [50 mmol/L Tris-HCl (pH 8.1), 10 mmol/L EDTA, 1% SDS, protease inhibitor cocktail]. DNA was sheared to small fragments of 200 to 900 bp by sonication. The supernatant was recovered, diluted, and precleared using herring sperm DNA/protein G-Sepharose slurry (Sigma). The recovered supernatant was incubated with either anti-HIF-1{alpha} antibody or an isotype control IgG for 2 hours in the presence of herring sperm DNA and protein G-Sepharose beads. The beads were washed with low-salt, high-salt, and LiCl buffers. The immunoprecipitated DNA was retrieved from the beads with 1% SDS and 1.1 mol/L NaHCO3 solution at 65°C for 6 hours. DNA was then purified using a PCR purification kit (Qiagen), and PCR was done on the extracted DNA using COX-2 promoter-specific primers forward (5'-GAATTTACCTTTCCCGCCTCTC-3') and reverse (5'-AAGCCCGGTGGGGGCAGGGTTT-3').

VEGF quantification. VEGF level was determined in growth medium using a VEGF ELISA (R&D Systems, Arbington, United Kingdom) following the manufacturer's instructions. The growth medium was removed and cleared by centrifugation, and adherent cells were counted. The level of VEGF was determined in samples at two different dilutions (1:1 and 1:10) in triplicate and standardized to cell number.

Determination of PGE2 levels. PGE2 levels were measured using a competitive enzyme immunoassay for PGE2 (Cayman Europe) following the manufacturer's protocol.

Statistical analysis. Statistical tests were carried out using t test done on Microsoft Excel. Statistical significance was determined and expressed as P ≤ 0.01.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
COX-2 protein expression is up-regulated in colorectal tumor cells in response to hypoxia. To achieve a further understanding of the regulatory networks controlling COX-2 expression, we sought to investigate the role of an important microenvironmental factor, hypoxia, in COX-2 regulation. For this, colorectal carcinoma (HT29 and HCT116), colorectal adenoma (AA/C1), and in vitro–transformed adenoma (AA/C1/SB10C) cells were subjected to growth under hypoxic conditions (1% O2), and protein extracts were prepared over time (Fig. 1A ). Immunoblot analysis confirmed that cells were exposed to hypoxia, as HIF-1{alpha} was rapidly induced in both colorectal adenoma and carcinoma cells (Fig. 1A). Interestingly, COX-2 protein levels increased in a time-dependent manner on exposure to hypoxia in all the cell lines used (Fig. 1A) irrespective of the basal levels of COX-2 expressed by these cells. It is important to note that, in response to hypoxia, HIF-1{alpha} induction preceded COX-2 up-regulation (Fig. 1A). Interestingly, COX-1 protein levels did not change in response to hypoxia in any of the cell lines used (data not shown).


Figure 1
View larger version (18K):
[in this window]
[in a new window]
  		Figure 1. COX-2 up-regulation in colorectal tumor cells during hypoxia. A, Western blot analyses for HIF-1{alpha} and COX-2 protein levels during hypoxia. Colorectal tumor cell lines (carcinoma cells, HT29 and HCT116; adenoma cells, AA/C1; and in vitro–transformed adenoma, AA/C1/SB10C), which express different basal levels of COX-2 (6, 50), were exposed to hypoxia (1% O2), and HIF-1{alpha} and COX-2 protein levels were analyzed by Western blotting over time as indicated. {alpha}-Tubulin was used as a protein loading control. B, HT29 cells were transiently transfected with the COX-2 promoter luciferase reporter and pRL-SV40 plasmids and grown in either normoxia (N) or hypoxia (H) for 16 hours. The luciferase activity was determined. Columns, mean of three independent experiments; bars, SD. C, Northern blot analysis for COX-2 mRNA levels in HT29 cells exposed to hypoxia for the indicated time using a biotinylated COX-2 probe. The 18S rRNA was used as a control for equal loading. D, examination of COX-2 mRNA decay in HT29 cells after growth in hypoxia/normoxia. HT29 cells were exposed to hypoxia/normoxia for 16 hours and transferred to normoxia after treatment with 10 µmol/L actinomycin-D. Cells were harvested every hour over a 3-hour period, and COX-2 mRNA levels were analyzed by Northern blotting.

 
COX-2 is transcriptionally up-regulated during hypoxia. Having shown COX-2 up-regulation by hypoxia in colorectal tumor cells, we aimed to gain some insights into the mechanism underlying this up-regulation. Initially, we used a luciferase reporter assay using a COX-2 promoter to assess the COX-2 promoter activity during hypoxia. Exposure of HT29 to hypoxia for 16 hours resulted in an ~3-fold increase in COX-2 promoter reporter activity compared with normoxia (Fig. 1B), suggesting that hypoxia may enhance transcription from the COX-2 promoter. This observation was supported by Northern blot analysis, revealing that COX-2 mRNA levels increased in HT29 cells growing under hypoxic conditions in a time-dependent manner (Fig. 1C). To further confirm that the increase in COX-2 mRNA levels is a result of transcriptional activation rather than mRNA stabilization, the rate of COX-2 mRNA decay following the inhibition of transcription was examined. HT29 cells growing in hypoxia for 16 hours were transferred to normoxia after treatment with 10 µmol/L actinomycin-D. Cells were harvested every hour over a 3-hour period, and COX-2 mRNA levels were analyzed by Northern blotting. The results revealed similar kinetics of COX-2 mRNA decay in cells growing in normoxia (Fig. 1D), suggesting that hypoxia does not confer stabilization of COX-2 mRNA. Taken together, these data suggested that COX-2 is a hypoxia-responsive gene, whose expression can be transcriptionally enhanced in colorectal tumor cells on exposure to hypoxia.

COX-2 up-regulation is associated with HIF-1{alpha} induction. Because COX-2 was transcriptionally up-regulated in hypoxic HT29 cells and given the critical role that HIF-1 plays in the cellular transcriptional response to hypoxia, we investigated whether HIF-1 is involved in hypoxia-mediated COX-2 up-regulation. To examine the association between HIF-1{alpha} induction and COX-2 up-regulation, HT29 cells were treated with increasing concentrations of the hypoxia surrogate deferoxamine (a specific HIF-1{alpha} inducer) for 16 hours. Western blot analysis revealed the deferoxamine treatment induced HIF-1{alpha} and also increased COX-2 protein levels in HT29 cell in a dose-dependent manner (Fig. 2A, left ). Additionally, transient ectopic expression of HIF-1{alpha} in HT29 cells, achieved by transfection with a mutant HIF-1{alpha} that is resistant to degradation (34), resulted in ~2.5-fold increase in COX-2 protein levels in normoxia compared with HT29 cells transfected with the vector-only control plasmid (Fig. 2A, middle). This increase in COX-2 protein levels was consistent in several experiments, ranging from 2- to 3-fold. Furthermore, inhibiting HIF-1{alpha} induction during hypoxia using 200 µmol/L YC-1 (32) abolished hypoxia-mediated COX-2 up-regulation (Fig. 2A, right). Altogether, these observations suggest that HIF-1 is involved in hypoxia-induced COX-2 up-regulation.


Figure 2
View larger version (71K):
[in this window]
[in a new window]
  		Figure 2. Direct involvment for HIF-1 in COX-2 up-regulation during hypoxia in colorectal cancer cells. A, association between HIF-1{alpha} induction and COX-2 up-regulation. A, left, Western blot analysis for HIF-1{alpha} and COX-2 protein levels in HT29 cells treated with increasing concentrations of the HIF-1{alpha}-specific inducer deferoxamine (DFO). A, middle, HT29 cells were transiently transfected with either the pcDNA3 (V), vector control, or the pcDNA3-HIF-1{alpha} (HIF-1{alpha}) expression vector, and the levels of HIF-1{alpha} and COX-2 were analyzed by Western blotting. A, right, effect of HIF-1{alpha} inhibition on COX-2 up-regulation during hypoxia in HT29 cells. HT29 cells were exposed to hypoxia in the presence of increasing concentrations of the guanylyl cyclase inhibitor YC-1 for 16 hours and then followed by Western blotting for HIF-1{alpha} and COX-2. B, nucleotide sequence of the COX-2 promoter. Bold uppercase letters, core sequences of the four HREs, CGTG; bold lowercase letters, transcription start point; underlined, restriction sites used in the subcloning of shorter fragments of the COX-2 promoter. Diagrammatic representation of the progressively shorter fragments of the COX-2 promoter [full length (P1), deleted HRE1 (P2), deleted HRE1 and HRE2 (P3), and deleted HRE3 (P4)] and their relative location. Relative luciferase reporter activity of the different promoter constructs after transfection in HT29 cells and exposure to hypoxia. Columns, mean of three independent experiments done in triplicates; bars, SD. C, top, oligonucleotides used in the pull-down assay. The WT oligonucleotide corresponds to fragment –519 to –490 from the COX-2 promoter [highlighted in (B)] and contains a HRE core sequence (underlined, position –506); this sequence was mutated in the mutant (Mut) oligonucleotide (underlined). C, bottom, oligonucleotide pull-down assay. HT29 cells were grown in normoxia or hypoxia for 16 hours, and nuclear protein extracts were prepared. The pull-down assay was done as described in Materials and Methods, samples were denatured and resolved on SDS-PAGE, and then blots were probed with HIF-1{alpha} monoclonal antibody. D, ChIP assay. HT29 cells were grown in normoxia/hypoxia for 16 hours, cells were then fixed and lysed, and DNA was sheared by sonication to 200- to 900-bp fragments (DNA shearing efficacy was assessed by gel electrophoresis). Immunoprecipitation was carried out using an HIF-1{alpha} monoclonal antibody or an irrelevant mouse IgG. The protein DNA complexes were denatured, and DNA was recovered and purified using a PCR purification kit. A PCR using COX-2 promoter primer was done on the input (genomic DNA) from normoxia- and hypoxia-treated HT29 cells as well as the immunoprecipitated DNA (using HIF-1{alpha} and mouse IgG). PCR products were analyzed by gel electrophoresis, and the size of the COX-2 promoter fragment was determined using the DNA marker (M).

 
HIF-1 directly binds to the COX-2 promoter. Having established an association between HIF-1{alpha} induction and COX-2 up-regulation, a direct involvement for HIF-1 in COX-2 transcription was investigated. HIF-1 has been shown to bind HRE on promoters of target genes and activate their transcription (23). Screening of the COX-2 promoter region for HIF-1-binding sites revealed the presence of four putative HRE consensuses (HRE1, HRE2, HRE3, and HRE4) in the sense orientation (Fig. 2B). From these four HRE sites, only the HRE3 (5'-GACGTGACTT-3') located at position 506 upstream the transcription initiation point (–506) fulfilled the criteria for mammalian HRE. Indeed, COX-2 promoter deletion analysis suggested the importance of HRE3 in the responsiveness of COX-2 promoter to hypoxia, as deletion of HRE3 abolished hypoxia-mediated activation of the COX-2 promoter reporter (Fig. 2B). To test the physical interaction of HIF-1 with the HRE3 of the human COX-2 promoter, we used biotinylated double-stranded oligonucleotides (Fig. 2C) coupled to streptavidin agarose beads to pull-down proteins interacting with the HRE3 in HT29 cells growing in normoxia or hypoxia. The bound protein complexes were then analyzed by Western blotting. As shown in Fig. 2C, HIF-1{alpha} bound to the WT HRE3 oligonucleotide but not to a similar oligonucleotide with the HRE3 mutated. The binding capacity of HIF-1{alpha} to the WT oligonucleotide decreased progressively with the addition of increasing amounts of the nonbiotinylated WT oligonucleotide in a competition assay (Fig. 2C). These results indicate that HIF-1{alpha} directly binds the HRE3 derived from the COX-2 promoter. We next did ChIP to determine whether HIF-1 binds the COX-2 promoter in HT29 cells. As shown in Fig. 2D, the anti-HIF-1{alpha} antibody, but not the control IgG antibody, precipitated the COX-2 promoter fragment spanning HRE3 in hypoxic HT29 cells. These data show that HIF-1 binds the COX-2 promoter at HRE3 site located at –506.

COX-2 up-regulation in hypoxia results in increased PGE2 levels. Previous reports have shown a critical role for the COX-2 metabolite PGE2 in colorectal tumorigenesis (15). Having shown COX-2 up-regulation in hypoxia, we examined whether PGE2 levels also increase in hypoxia. HT29 cells were subjected to growth under hypoxic conditions in the presence or absence of the COX-2-selective inhibitor NS-398 for 16 hours, and the levels of PGE2 in the growth medium were determined. There was a 4-fold increase in PGE2 levels in hypoxia compared with normoxia (Fig. 3A ). Furthermore, the increase in PGE2 during hypoxia was inhibited by treatment with 10 µmol/L COX-2-selective inhibitor NS-398 (this dose was reported previously to selectively inhibit COX-2 activity with no effect on cell growth; ref. 35). Therefore, we conclude that, in response to hypoxia, there is a COX-2-dependent increase in PGE2 levels.


Figure 3
View larger version (26K):
[in this window]
[in a new window]
  		Figure 3. The effect of COX-2 up-regulation on colorectal cancer cell growth and survival during hypoxia. A, COX-2 up-regulation during hypoxia results in increased PGE2 levels. HT29 cells were exposed to normoxia or hypoxia in the presence or absence of 10 µmol/L COX-2-selective inhibitor NS-398 for 24 hours, and then PGE2 levels were determined in the growth medium using a commercial ELISA and standardized to cell number. Columns, mean of three experiments done in triplicate; bars, SD. B, effect of hypoxia on cell growth and survival during hypoxia. HT29 cells were exposed to normoxia or hypoxia for 24 hours, and the number of adherent and floating apoptotic cells were determined as described in Materials and Methods. Columns, mean of three independent experiments done in triplicate; bars, SD. (*, P ≤ 0.01). B, bottom, Based on DNA content, cell cycle analyses were also done on HT29 cells growing in normoxia and hypoxia. The data are examples of one experiment done six times independently. C, PGE2 promotes cancer cell growth and survival under hypoxic conditions. HT29 cells were treated in hypoxia with NS-398 (10 µmol/L), PGE2 (1 µmol/L), or a combination of both for 24 hours to examine the effect of PGE2 on cell growth and survival under hypoxic conditions. The number of attached and floating apoptotic cells were determined as described in Materials and Methods. Columns, mean of three different experiments done in triplicate; bars, SD.

 
PGE2 contributes to tumor cell growth and survival under hypoxic conditions. PGE2 has been shown previously to promote colorectal tumor cell growth and survival in normoxia (13, 14). This is believed to be one of the mechanisms underlying the oncogenic role of COX-2 in colorectal tumorigenesis. Here, we hypothesized that the increased levels of PGE2 during hypoxia may also promote cell growth and survival under hypoxic conditions. Initially, exposure of HT29 cells to hypoxia for 24 hours resulted in a reduction in cell yield (Fig. 3B, top, left), increased levels of cell death (Fig. 3B, top, right), and a decreased rate of cell proliferation with more cells accumulating in G1 phase of the cell cycle (Fig. 3B, bottom). To assess the direct consequence of COX-2 on cell survival under hypoxia, COX-2 was selectively inhibited with 10 µmol/L COX-2-selective inhibitor NS-398, and cell yield was determined. In normoxia, NS-398 (10 µmol/L) treatment had no significant effect on cell yield (data not shown; reported in ref. 35), and as predicted, PGE2 treatment on its own significantly enhanced cell growth (data not shown; reported in ref. 36). In hypoxia, NS-398 (10 µmol/L) treatment potentiated the inhibitory effect of hypoxia on cell yield (Fig. 3C, top) with a significant increase in cell death (Fig. 3C, bottom). The inhibitory effect of NS-398 on cell survival under hypoxia was overcome by the addition of exogenous PGE2 (Fig. 3C). Treatment with PGE2 on its own promoted cancer cell growth and survival in hypoxia (Fig. 3C). Taken together, these results indicated that PGE2 as a result of COX-2 activity plays an important role in promoting colorectal cancer cell growth and survival during hypoxia.

PGE2 enhances HIF-1 transcriptional activation during hypoxia. To examine a possible cross-talk between COX-2/PGE2 and HIF-1 pathways, we decided to investigate whether PGE2 affected HIF-1 expression or activity. PGE2, at relatively high concentrations, has been reported previously to increase the expression of HIF-1{alpha} in HCT116 cells (37). In normoxia, PGE2 alone at a relatively low dose (1 µmol/L) that we have shown previously to stimulate growth and survival of colorectal cancer cells (36) failed to induce HIF-1{alpha} (Fig. 4A ) and had no effect on HIF-1ß levels. Similarly, under hypoxic conditions, exogenous PGE2 (1 µmol/L) and NS-398 (10 µmol/L) treatment had no effect on HIF-1{alpha}/HIF-1ß expression levels (Fig. 4A). Interestingly, however, hypoxia-induced HIF-1 transcriptional activity was partly inhibited by NS-398 treatment, suggesting that PGE2 may enhance HIF-1 transcriptional activity in hypoxia (Fig. 4A). Indeed, subsequent addition of PGE2 overcame the inhibitory effect of NS-398 on HIF-1 transactional activity. These observations suggest that PGE2 enhances HIF-1 transcriptional activity in hypoxia.


Figure 4
View larger version (13K):
[in this window]
[in a new window]
  		Figure 4. PGE2 enhances HIF-1 transcriptional activity and VEGF production. A, HT29 cells were grown in normoxia/hypoxia and treated with NS-398 (10 µmol/L), PGE2 (1 µmol/L), or a combination of both for 16 hours. Western blot analyses were used to assess HIF-1{alpha}/HIF-1ß protein levels. An HRE luciferase reporter assay was used as described in Materials and Methods to assess HIF-1 transcriptional activity after treatment with PGE2. B, increased PGE2 levels during hypoxia result in enhanced VEGF production. HT29 cells were treated as described previously, and VEGF level was determined in the growth medium using a commercial ELISA. Columns, mean of three independent experiments standardized to cell counts; bars, SD.

 
VEGF, the critical proangiogenesis factor, is an important target of HIF-1. As PGE2 enhances HIF-1 transcriptional activity in hypoxia, we examined the role of PGE2 in VEGF regulation. PGE2 treatment resulted in the induction of VEGF in HT29 cells growing under normoxia (Fig. 4B). Exposing HT29 cells to hypoxia resulted in a further increase in VEGF production, which was partly inhibited by NS-398. The inhibitory effect of NS-398 on VEGF expression under hypoxia was recovered by PGE2 treatment (Fig. 4B). These observations correlate with HIF-1 transcriptional activity shown in Fig. 4A and indicated that PGE2 potentiates hypoxia-induced VEGF by enhancing HIF-1 transcriptional activity in the colon cancer cell line HT29.

PGE2 enhances HIF-1 transcriptional activity in hypoxia through the MAPK pathway. PGE2 has been shown to promote cell proliferation through the activation of MAPK pathway (15); we therefore examined whether increased levels of PGE2 during hypoxia activate the MAPK pathway. Consistent with previous reports, in normoxia, PGE2 activated the MAPK pathways by inducing ERK phosphorylation in HT29 cells (Fig. 5A ). In hypoxia, ERK was also activated, and its activation was partly inhibited with NS-398 treatment (Fig. 5A). However, the inhibitory effect of NS-398 on ERK activation in hypoxia was overcome by PGE2 treatment (Fig. 5A). These results indicate that increased levels of PGE2 during hypoxia activate the MAPK pathway.


Figure 5
View larger version (21K):
[in this window]
[in a new window]
  		Figure 5. PGE2 activates the MAPK pathway during hypoxia and enhances HIF-1 transcriptional activity through ERK activation. A, Western blot analysis was carried out to examine ERK activation in HT29 cells grown in normoxia/hypoxia in the presence or absence of NS-398, PGE2, or both. B, PGE2 enhances HIF-1 transcriptional activity through ERK activation. HT29 cells were exposed to growth under hypoxic conditions and treated as indicated, and, subsequently, ERK activation and HIF-1 transcriptional activity were examined.

 
Because the MAPK pathway has been reported to enhance HIF-1 transcriptional activity (38), it was hypothesized that increased levels of PGE2 by hypoxia may increase HIF-1 activity through activating the MAPK pathway. To test this hypothesis, HIF-1 activity was assessed in hypoxic HT29 cells treated with the MEK inhibitor U0126. Inhibition of MEK resulted in reduced transcriptional activity of HIF-1 similar to that observed with NS-398 treatment (Fig. 5B). However, whereas the addition of PGE2 overcame the effect of NS-398 on HIF-1 transcriptional activity, PGE2 did not reverse the effect of the MEK inhibitor. This suggests that PGE2 enhances HIF-1 transcriptional activity through ERK activation.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Adaptation to hypoxia is critical for tumor cell growth and survival and is achieved largely by transcriptional activation of genes that facilitate short- and long-term adaptive responses (17, 31). In the current study, we report for the first time that hypoxia induces COX-2 in colorectal tumor cells and show that this up-regulation is mediated directly by HIF-1. In addition, COX-2 up-regulation by hypoxia represents a critical adaptive mechanism that promotes colorectal tumor cell survival and angiogenesis under hypoxic conditions.

COX-2 overexpression has been described in tumors originating from different tissues (39), including colorectal tumors (3, 4), and compelling evidence supports an important role for COX-2 in tumorigenesis (8, 40, 41). Therefore, identifying the regulatory mechanisms that underlie COX-2 up-regulation is crucial for further understanding of the tumorigenic process and the development of novel approaches for cancer prevention and therapy. For colorectal tumors, deregulation of the Wnt and Ras signaling pathways have been reported to contribute to COX-2 up-regulation (16). Our findings identify hypoxia as a novel tumor microenvironmental factor that contributes to COX-2 up-regulation in colorectal tumor cells. It is of interest to note that, in response to hypoxia, COX-2 expression is enhanced in both colorectal adenoma and carcinoma cells, suggesting that hypoxia may contribute to COX-2 overexpression at early stages of colorectal tumorigenesis. Additionally, hypoxia up-regulates COX-2 expression in colorectal tumor cells with different basal levels of COX-2, suggesting that hypoxia may act synergistically with other pathways implicated in COX-2 up-regulation.

COX-2 up-regulation by hypoxia has been described previously in human umbilical vascular endothelial (42) and corneal epithelial cells (43) to be mediated by NF-{kappa}B and peroxisome proliferator-activated receptors, respectively. In addition, while this article was in preparation, Csiki et al. reported that COX-2 is up-regulated in hypoxic lung cancer cells in an HIF-1-dependent manner (44). Although the study of Csiki et al. was the first report to describe COX-2 as a HIF-1 target gene, we provide the first evidence to show that HIF-1 directly binds a specific HRE located at –506 on the COX-2 promoter and highlight the biological significance of COX-2 up-regulation during hypoxia. The oncogenic role of COX-2 in colorectal and other tumors is largely attributed to its role in prostaglandin biosynthesis (11). For colorectal tumorigenesis, PGE2 has been particularly and extensively studied (11). Here, we report that COX-2 up-regulation in hypoxia results in enhanced PGE2 production. Given the pivotal role of PGE2 in promoting colorectal tumor cell growth and survival, the results obtained in this work are particularly relevant to explain, at least in part, how colorectal tumor cells maintain their growth and survival under hypoxic conditions. Until now, great emphasis has been placed on the role of COX-2/PGE2 in tumor cell growth and survival under normoxic conditions, mediated by activating phosphatidylinositol 3-kinase/MAPK pathways (13) as well as up-regulating the prosurvival protein Bcl-2 (14). Our data provide further insight into the critical role of COX-2/PGE2 in promoting cell survival most importantly under hypoxic microenvironmental stress, which is typically known to inhibit cell growth (45) and, if persistent, cell death can ensue (19, 29). The increase in COX-2 and PGE2 levels in hypoxic colorectal tumor cells represents a novel short-term adaptive response that allows cell survival during hypoxia, which could have important implications for colorectal tumorigenesis. Although the mechanisms by which PGE2 promotes cell survival in hypoxia are not completely elucidated here, our data supported by previous reports (13, 15) suggest that it is likely to be occurring through the activation of MAPK.

In addition to mediating short-term survival and metabolic responses in tumors, hypoxia also induces long-term responses (i.e., angiogenesis; ref. 22), mediated chiefly by the secretion of VEGF (46). Recent reports showed that PGE2 can activate the "angiogenic switch" in COX-2-induced breast cancer progression (47). For colorectal tumors, in particular, COX-2 plays a critical role in VEGF induction and stimulation of angiogenesis (10). The data reported here not only emphasize the important role of PGE2 in increasing VEGF levels in colorectal cancer cells in normoxia but also reveal that increased PGE2 levels during hypoxia enhance hypoxia-mediated VEGF up-regulation. This potentiation is achieved by the effect of PGE2 in enhancing the transcriptional activity of HIF-1 through the activation of MAPK pathway, consistent with previous reports that described the involvement of MAPK pathways in the modulation of HIF-1 transcriptional activity (38). These findings highlight a cross-talk between HIF-1 and COX-2 pathway (Fig. 6 ). The ability of PGE2 to potentiate HIF-1 transcriptional activity is particularly interesting because HIF-1 is involved in the regulation of several other pathways implicated in tumorigenesis (48). Therefore, PGE2 up-regulation in colorectal tumor cells during hypoxia may modulate the expression of several other HIF-1-target genes, which could have implications for tumor cell survival, angiogenesis, invasion and metastasis, and subsequently tumor progression (Fig. 6).


Figure 6
View larger version (10K):
[in this window]
[in a new window]
  		Figure 6. Model for COX-2 regulation and its role in colorectal tumorigenesis. Mutations in Wnt and Ras signaling pathways can induce COX-2 in normoxic conditions, resulting in increased levels of PGE2, which promotes tumor cell growth/survival and stimulates angiogenesis. As reported by Wang, PGE2 can activate the Ras-MAPK pathway, thereby amplifying the expression of COX-2 and showing a positive feedback loop that contribute to COX-2 up-regulation (15). This positive feedback loop can be extended to our study under hypoxic conditions, where we show that HIF-1 can directly up-regulate COX-2 and PGE2 levels. PGE2 then activates the MAPK pathway and enhances HIF-1 transcriptional activity, resulting in a potential positive feedback loop that may act to maintain high COX-2 levels under hypoxic conditions.

 
The link between hypoxia and COX-2 established in this study suggests possible overlapping functions that collectively drive the progression of colorectal and potentially other solid tumors where hypoxia is commonly observed. Recently, PGE2 has been shown to amplify the expression of COX-2 during colorectal tumorigenesis through a positive feedback loop involving the constitutive activation of Ras-MAPK (15); this observation can be extended to our study. Increased levels of PGE2 during hypoxia, resulting from COX-2 up-regulation, potentiate HIF-1 transcriptional activity, which results in further up-regulation of COX-2 because we showed that COX-2 is a HIF-1 target gene. This positive feedback loop may be important in maintaining COX-2 overexpression in hypoxic colorectal tumor cells (Fig. 6).

In summary, our findings provide further evidence that hypoxia promotes tumor progression by modulating gene expression. In colorectal tumor cells, COX-2 is transcriptionally induced by hypoxia via HIF-1, and its up-regulation contributes to maintaining tumor survival and potentially promoting angiogenesis. Thus, COX-2 overexpression can be regarded as a critical adaptive response to hypoxia, which mediates both short- (survival) and long-term adaptation (angiogenesis). Because tumor hypoxia could be a target for selective cancer therapy (49), our findings suggest that pharmacologic targeting of COX-2 using modified COX-2-selective inhibitors that can only be activated under hypoxic conditions could increase the selectivity of the current COX-2-selective inhibitors.


   Acknowledgments
 
Grant support: Algerian Government, a program grant from Cancer Research UK, and the Citrina Foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Peter Ratcliffe for providing the HIF-1{alpha} expression vector, Stephen Prescott for providing the COX-2 promoter reporter, and Karim Malik (Bristol University, Bristol, United Kingdom) for his help with the molecular biology work.

Received 2/ 2/06. Revised 4/ 3/06. Accepted 4/21/06.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159–70.[CrossRef][Medline]
  2. Williams AC, Harper SJ, Paraskeva C. Neoplastic transformation of a human colonic epithelial cell line: in vitro evidence for the adenoma to carcinoma sequence. Cancer Res 1990;50:4724–30.[Abstract/Free Full Text]
  3. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase-2 gene-expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183–8.[Medline]
  4. Elder DJ, Baker JA, Banu NA, Moorghen M, Paraskeva C. Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J Pathol 2002;198:428–34.[CrossRef][Medline]
  5. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005;23:2840–55.[Abstract/Free Full Text]
  6. Elder DJ, Halton DE, Crew TE, Paraskeva C. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 2000;86:553–60.[CrossRef][Medline]
  7. Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997;3:1679–83.[Abstract]
  8. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–52.[Abstract/Free Full Text]
  9. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc({Delta}716) knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803–9.[CrossRef][Medline]
  10. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705–16.[CrossRef][Medline]
  11. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55:115–22.[Free Full Text]
  12. Pugh S, Thomas GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994;35:675–8.[Abstract/Free Full Text]
  13. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075–81.[Abstract/Free Full Text]
  14. Sheng HM, Shao JY, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E-2 in human colon cancer cells. Cancer Res 1998;58:362–6.[Abstract/Free Full Text]
  15. Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 2005;65:1822–9.[Abstract/Free Full Text]
  16. Araki Y, Okamura S, Hussain SP, et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003;63:728–34.[Abstract/Free Full Text]
  17. Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38–47.[CrossRef][Medline]
  18. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000;35:71–103.[CrossRef][Medline]
  19. Fei P, Wang W, Kim SH, et al. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 2004;6:597–609.[CrossRef][Medline]
  20. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88–91.[CrossRef][Medline]
  21. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002;64:993–8.[CrossRef][Medline]
  22. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677–84.[CrossRef][Medline]
  23. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor-1 is a basic-helix-loop-helix-pas heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995;92:5510–4.[Abstract/Free Full Text]
  24. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-{alpha} to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468–72.[Abstract/Free Full Text]
  25. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1{alpha}. Modulation of transcriptional activity by oxygen tension. J Biol Chem 1997;272:19253–60.[Abstract/Free Full Text]
  26. Arany Z, Huang LE, Eckner R, et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A 1996;93:12969–73.[Abstract/Free Full Text]
  27. Wenger RH, Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 1997;378:609–16.[Medline]
  28. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1{alpha} in common human cancers and their metastases. Cancer Res 1999;59:5830–5.[Abstract/Free Full Text]
  29. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1{alpha} or in hypoxia-mediated apoptosis, cell proliferation, and tumour angiogenesis. Nature 1998;394:485–90.[CrossRef][Medline]
  30. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1997;94:8104–9.[Abstract/Free Full Text]
  31. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62–7.[CrossRef][Medline]
  32. Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516–25.[Abstract/Free Full Text]
  33. Patsos HA, Hicks DJ, Dobson RR, et al. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut 2005;54:1741–50.[Abstract/Free Full Text]
  34. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-{alpha} chains activated by prolyl hydroxylation. EMBO J 2001;20:5197–206.[CrossRef][Medline]
  35. Crew TE, Elder DJ, Paraskeva C. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Carcinogenesis 2000;21:69–77.[Abstract/Free Full Text]
  36. Chell SD, Witherden IR, Dobson RR, et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 2006;66:3106–13.[Abstract/Free Full Text]
  37. Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003;63:2330–4.[Abstract/Free Full Text]
  38. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 2003;278:14013–9.[Abstract/Free Full Text]
  39. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637–45.[CrossRef][Medline]
  40. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc {delta}716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803–9.[CrossRef][Medline]
  41. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11–21.[CrossRef][Medline]
  42. Schmedtje JF, Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-{kappa}B p65 transcription factor in human vascular endothelial cells. Circulation 1996;94:2392.
  43. Bonazzi A, Mastyugin V, Mieyal PA, Dunn MW, Laniado-Schwartzman M. Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium. J Biol Chem 2000;275:2837–44.[Abstract/Free Full Text]
  44. Csiki I, Yanagisawa K, Haruki N, et al. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1{alpha} in non-small cell lung cancer. Cancer Res 2006;66:143–50.[Abstract/Free Full Text]
  45. Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL, Dang CV. Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem 2001;276:7919–26.[Abstract/Free Full Text]
  46. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353–64.[CrossRef][Medline]
  47. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E-2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004;101:591–6.[Abstract/Free Full Text]
  48. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721–32.[CrossRef][Medline]
  49. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 2003;94:1021–8.[CrossRef][Medline]
  50. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254–9.[Medline]



This article has been cited by other articles:


Home page
 CarcinogenesisHome page
A. E. Moore, A. Greenhough, H. R. Roberts, D. J. Hicks, H. A. Patsos, A. C. Williams, and C. Paraskeva
HGF/Met signalling promotes PGE2 biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells
Carcinogenesis, October 1, 2009; 30(10): 1796 - 1804.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K.-Y. Chang, M.-R. Shen, M.-Y. Lee, W.-L. Wang, W.-C. Su, W.-C. Chang, and B.-K. Chen
Epidermal Growth Factor-activated Aryl Hydrocarbon Receptor Nuclear Translocator/HIF-1{beta} Signal Pathway Up-regulates Cyclooxygenase-2 Gene Expression Associated with Squamous Cell Carcinoma
J. Biol. Chem., April 10, 2009; 284(15): 9908 - 9916.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Greenhough, H. J.M. Smartt, A. E. Moore, H. R. Roberts, A. C. Williams, C. Paraskeva, and A. Kaidi
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment
Carcinogenesis, March 1, 2009; 30(3): 377 - 386.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Ahmadi, D. C. Emery, and D. J. Morgan
Prevention of Both Direct and Cross-Priming of Antitumor CD8+ T-Cell Responses following Overproduction of Prostaglandin E2 by Tumor Cells In vivo
Cancer Res., September 15, 2008; 68(18): 7520 - 7529.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Mizukami, Y. Kohgo, and D. C. Chung
Hypoxia Inducible Factor-1 Independent Pathways in Tumor Angiogenesis
Clin. Cancer Res., October 1, 2007; 13(19): 5670 - 5674.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Spinella, L. Rosano, V. Di Castro, S. Decandia, M. R. Nicotra, P. G. Natali, and A. Bagnato
Endothelin-1 and Endothelin-3 Promote Invasive Behavior via Hypoxia-Inducible Factor-1{alpha} in Human Melanoma Cells
Cancer Res., February 15, 2007; 67(4): 1725 - 1734.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaidi, A.
Right arrow Articles by Paraskeva, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaidi, A.
Right arrow Articles by Paraskeva, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online